Objective To report the results of a double-blind, placebofor example from species of Pinus, Picea or Hypoxis, with b-sitosterol as the main component. controlled trial to evaluate AzuprostatA , a b-sitosterol, in patients with symptoms of outlet obstruction causedResults There were significant (P<0.01) improvements over placebo in those treated with b-sitosterol; the by benign prostatic hyperplasia (BPH). Patients and methods A randomized, double-blind mean diÂerence in the IPSS between placebo and b-sitosterol, adjusted for the initial values, was 5.4 and placebo-controlled clinical trial was conducted to assess the eÃcacy and safety of 130 mg free and in the quality-of-life index was 0.9. There were also significant improvements in the secondary outb-sitosterol (phytosterol) daily, using the international prostate symptom score (IPSS) as the primary outcome come variables, with an increase in Q max (4.5 mL/s) and decrease in PVR (33.5 mL) in favour of b-sitosterol variable. In total, 177 patients with BPH were recruited for 6 months of treatment in 13 study when adjusted for the changes after placebo. Conclusion These results show that b-sitosterol is an centres. In addition to the relative diÂerence in the IPSS, changes in quality of life, peak urinary flow rate eÂective option in the treatment of BPH. Keywords b-sitosterol therapy, symptom score, benign (Q max ) and post-void residual urinary volume (PVR) were recorded. The drug used in the trial consisted of prostatic hyperplasia a chemically defined extract of phytosterols, derived BPH (1991 and1993) [13,14] and reports the results

No abstract

This study investigates the hypothesis that HIV/AIDS epidemic slows down the pace of economic growth. We examine 41 Sub‐Saharan African countries by using the empirical growth equation in an augmented Solow model in which health capital serves as a determinant of human capital. Econometric analysis is based on panel data and covers the period 1997‐2005. We control for a variety of factors possibly correlated with HIV prevalence that might also influence economic growth. As a key result we prove that the epidemic has a significant negative effect on the growth rate of per capita GDP in Sub‐Saharan Africa.

No abstract

No abstract